Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 2, 2015, Pages 265-275

  Dhar, Swati ^a   Kumar, Avinash ^a   Li, Kun ^a   Tzivion, Guri ^a   Levenson, Anait S ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylation; MTA1; Prostate cancer; PTEN; Resveratrol

Indexed keywords

HISTONE DEACETYLASE; MTA1 PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; RESVERATROL; UNCLASSIFIED DRUG; HISTONE DEACETYLASE INHIBITOR; MTA1 PROTEIN, HUMAN; NUCLEOSOME; PROTEIN BINDING; PTEN PROTEIN, HUMAN; REPRESSOR PROTEIN; STILBENE DERIVATIVE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SURVIVAL; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL NUCLEUS; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; GENE SILENCING; IMMUNOPRECIPITATION; METABOLISM; NUCLEOSOME; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; DOWN-REGULATION; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; MALE; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MICE, NUDE; MODELS, BIOLOGICAL; NUCLEOSOMES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STILBENES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84913582432     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.11.004     Document Type: Article

References (57)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
2. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
3. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., Reddy G.P. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002, 62:2488-2492.
4. Pozo-Guisado E., Lorenzo-Benayas M.J., Fernandez-Salguero P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int. J. Cancer 2004, 109:167-173.
5. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001, 15:1798-1800.
6. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., Lin P.Y., Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10:2190-2202.
7. Kimura Y., Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131:1844-1849.
8. Toh Y., Pencil S.D., Nicolson G.L. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J. Biol. Chem. 1994, 269:22958-22963.
9. Xue Y., Wong J., Moreno G.T., Young M.K., Cote J., Wang W. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 1998, 2:851-861.
10. Kai L., Samuel S.K., Levenson A.S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 2010, 126:1538-1548.
11. Li K., Dias S.J., Rimando A.M., Dhar S., Mizuno C.S., Penman A.D., Lewin J.R., Levenson A.S. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One 2013, 8:e57542.
12. Kai L., Wang J., Ivanovic M., Chung Y.T., Laskin W.B., Schulze-Hoepfner F., Mirochnik Y., Satcher R.L., Levenson A.S. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate 2011, 71:268-280.
13. Dias S.J., Zhou X., Ivanovic M., Gailey M.P., Dhar S., Zhang L., He Z., Penman A.D., Vijayakumar S., Levenson A.S. Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Sci. Rep. 2013, 3:2331.
14. Hofer M.D., Kuefer R., Varambally S., Li H., Ma J., Shapiro G.I., Gschwend J.E., Hautmann R.E., Sanda M.G., Giehl K., Menke A., Chinnaiyan A.M., Rubin M.A. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004, 64:825-829.
15. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
16. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
17. Lim M.A., Yang L., Zheng Y., Wu H., Dong L.Q., Liu F. Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells. Oncogene 2004, 23:9348-9358.
18. Dey N., Crosswell H.E., De P., Parsons R., Peng Q., Su J.D., Durden D.L. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008, 68:1862-1871.
19. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13513-13518.
20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
21. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Res. 2011, 71:629-633.
22. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2110-2115.
23. Emiliani S., Fischle W., Van Lint C., Al-Abed Y., Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2795-2800.
24. Molli P.R., Singh R.R., Lee S.W., Kumar R. MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. Oncogene 2008, 27:1971-1980.
25. Mazumdar A., Wang R.A., Mishra S.K., Adam L., Bagheri-Yarmand R., Mandal M., Vadlamudi R.K., Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat. Cell Biol. 2001, 3:30-37.
26. Pan L., Lu J., Wang X., Han L., Zhang Y., Han S., Huang B. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007, 109:1676-1688.
27. Reddy S.D., Pakala S.B., Molli P.R., Sahni N., Karanam N.K., Mudvari P., Kumar R. Metastasis-associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J. Biol. Chem. 2012, 287:27843-27850.
28. Salot S., Gude R.P. MTA1 aids the Akt pathway by inhibiting expression of a key regulator, PTEN. J. Cancer Sci. Ther. 2010, 2:114-119.
29. Nicolson G.L., Nawa A., Toh Y., Taniguchi S., Nishimori K., Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin. Exp. Metastasis 2003, 20:19-24.
30. Moon W.S., Chang K., Tarnawski A.S. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: Relationship to vascular invasion and estrogen receptor-alpha. Hum. Pathol. 2004, 35:424-429.
31. Martin M.D., Hilsenbeck S.G., Mohsin S.K., Hopp T.A., Clark G.M., Osborne C.K., Allred D.C., O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res. Treat. 2006, 95:7-12.
32. Zhu X., Guo Y., Li X., Ding Y., Chen L. Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J. Thoracic Oncol. 2010, 5:1159-1166.
33. Li S.H., Tian H., Yue W.M., Li L., Gao C., Li W.J., Hu W.S., Hao B. Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J. Surg. 2012, 36:623-631.
34. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
35. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98:604-610.
36. Okumura K., Mendoza M., Bachoo R.M., DePinho R.A., Cavenee W.K., Furnari F.B. PCAF modulates PTEN activity. J. Biol. Chem. 2006, 281:26562-26568.
37. Ikenoue T., Inoki K., Zhao B., Guan K.L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008, 68:6908-6912.
38. Hardy T.M., Tollefsbol T.O. Epigenetic diet: impact on the epigenome and cancer. Epigenomics 2011, 3:503-518.
39. Chen J., Xu X. Diet, epigenetic, and cancer prevention. Adv. Genet. 2010, 71:237-255.
40. Link A., Balaguer F., Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 2010, 80:1771-1792.
41. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
42. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5246-5250.
43. Gray I.C., Stewart L.M., Phillips S.M., Hamilton J.A., Gray N.E., Watson G.J., Spurr N.K., Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 1998, 78:1296-1300.
44. Zu K., Martin N.E., Fiorentino M., Flavin R., Lis R.T., Sinnott J.A., Finn S., Penney K.L., Ma J., Fazli L., Gleave M.E., Bismar T.A., Stampfer M.J., Pollak M.N., Loda M., Mucci L.A., Giovannucci E. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol. Biomark. Prev. 2013, 22:1984-1993.
45. Ayala G.E., Dai H., Ittmann M., Li R., Powell M., Frolov A., Wheeler T.M., Thompson T.C., Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004, 64:6082-6090.
46. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
47. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221.
48. Wang Y., Romigh T., He X., Orloff M.S., Silverman R.H., Heston W.D., Eng C. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum. Mol. Genet. 2010, 19:4319-4329.
49. Dhar S., Hicks C., Levenson A.S. Resveratrol and prostate cancer: promising role for microRNAs. Mol. Nutr. Food Res. 2011, 55:1219-1229.
50. Gan Y.H., Zhang S. PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol. 2009, 45:e150-e154.
51. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of PTEN. J. Cell Sci. 2008, 121:249-253.
52. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
53. Gericke A., Munson M., Ross A.H. Regulation of the PTEN phosphatase. Gene 2006, 374:1-9.
54. Chung J.H., Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005, 65:8096-8100.
55. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
56. Li A.G., Piluso L.G., Cai X., Wei G., Sellers W.R., Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 2006, 23:575-587.
57. Chang C.J., Mulholland D.J., Valamehr B., Mosessian S., Sellers W.R., Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 2008, 28:3281-3289.